The following are some key points that we have chosen to highlight in connection with the report:

· Net sales affected by import restrictions – stronger quarters expected ahead
· Continued stable cost base
· Rights issue of SEK 4.1m for continued expansion

Read our comment on the report here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
 
This is a press release from Analyst Group regarding the publication of a comment on ODI Pharma. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.